🚀 VC round data is live in beta, check it out!
Philogen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Philogen and similar public comparables like Ventyx Biosciences, HK inno.N, Pacira BioSciences, Amphastar Pharma and more.
Philogen Overview
About Philogen
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Founded
1996
HQ
Employees
183
Website
Sectors
Financials (LTM)
EV
$571M
Philogen Financials
Philogen reported last 12-month revenue of $289M and EBITDA of $230M.
In the same LTM period, Philogen generated $230M in EBITDA and $200M in net income.
Revenue (LTM)
Philogen P&L
In the most recent fiscal year, Philogen reported revenue of $372M and EBITDA of $313M.
Philogen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $289M | XXX | $372M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $364M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $230M | XXX | $313M | XXX | XXX | XXX |
| EBITDA Margin | 80% | XXX | 84% | XXX | XXX | XXX |
| EBIT Margin | 78% | XXX | 83% | XXX | XXX | XXX |
| Net Profit | $200M | XXX | $274M | XXX | XXX | XXX |
| Net Margin | 69% | XXX | 74% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Philogen Stock Performance
Philogen has current market cap of $1B, and enterprise value of $571M.
Market Cap Evolution
Philogen's stock price is $24.98.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $571M | $1B | 1.5% | XXX | XXX | XXX | $6.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPhilogen Valuation Multiples
Philogen trades at 2.0x EV/Revenue multiple, and 2.5x EV/EBITDA.
EV / Revenue (LTM)
Philogen Financial Valuation Multiples
As of April 18, 2026, Philogen has market cap of $1B and EV of $571M.
Equity research analysts estimate Philogen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Philogen has a P/E ratio of 5.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $571M | XXX | $571M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 2.5x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBIT | 2.5x | XXX | 1.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 1.6x | XXX | XXX | XXX |
| P/E | 5.0x | XXX | 3.7x | XXX | XXX | XXX |
| EV/FCF | 3.8x | XXX | 1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Philogen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Philogen Margins & Growth Rates
Philogen's revenue in the last 12 month declined by (74%).
Philogen's revenue per employee in the last FY averaged $2.0M, while opex per employee averaged $0.3M for the same period.
Philogen's rule of 40 is (38%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Philogen's rule of X is (151%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Philogen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (74%) | XXX | (76%) | XXX | XXX | XXX |
| EBITDA Margin | 80% | XXX | 84% | XXX | XXX | XXX |
| EBITDA Growth | (92%) | XXX | (89%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (38%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (151%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Philogen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Philogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Ventyx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| HK inno.N | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Amphastar Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Philogen M&A Activity
Philogen acquired XXX companies to date.
Last acquisition by Philogen was on XXXXXXXX, XXXXX. Philogen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Philogen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPhilogen Investment Activity
Philogen invested in XXX companies to date.
Philogen made its latest investment on XXXXXXXX, XXXXX. Philogen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Philogen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Philogen
| When was Philogen founded? | Philogen was founded in 1996. |
| Where is Philogen headquartered? | Philogen is headquartered in Italy. |
| How many employees does Philogen have? | As of today, Philogen has over 183 employees. |
| Who is the CEO of Philogen? | Philogen's CEO is Professor Dario Neri. |
| Is Philogen publicly listed? | Yes, Philogen is a public company listed on Borsa Italiana. |
| What is the stock symbol of Philogen? | Philogen trades under PHIL ticker. |
| When did Philogen go public? | Philogen went public in 2021. |
| Who are competitors of Philogen? | Philogen main competitors are Ventyx Biosciences, HK inno.N, Pacira BioSciences, Amphastar Pharma. |
| What is the current market cap of Philogen? | Philogen's current market cap is $1B. |
| What is the current revenue of Philogen? | Philogen's last 12 months revenue is $289M. |
| What is the current revenue growth of Philogen? | Philogen revenue growth (NTM/LTM) is (74%). |
| What is the current EV/Revenue multiple of Philogen? | Current revenue multiple of Philogen is 2.0x. |
| Is Philogen profitable? | Yes, Philogen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Philogen? | Philogen's last 12 months EBITDA is $230M. |
| What is Philogen's EBITDA margin? | Philogen's last 12 months EBITDA margin is 80%. |
| What is the current EV/EBITDA multiple of Philogen? | Current EBITDA multiple of Philogen is 2.5x. |
| What is the current FCF of Philogen? | Philogen's last 12 months FCF is $150M. |
| What is Philogen's FCF margin? | Philogen's last 12 months FCF margin is 52%. |
| What is the current EV/FCF multiple of Philogen? | Current FCF multiple of Philogen is 3.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.